메뉴 건너뛰기




Volumn 376, Issue 18, 2017, Pages 1713-1722

Evolocumab and clinical outcomes in patients with cardiovascular disease

(1,277)  Sabatine, Marc S a   Giugliano, Robert P a   Keech, Anthony C b   Honarpour, Narimon c   Wiviott, Stephen D a   Murphy, Sabina A a   Kuder, Julia F a   Wang, Huei c   Liu, Thomas c   Wasserman, Scott M c   Sever, Peter S d   Pedersen, Terje R e   Fish, M P f   Abrahamsen, T E f   Im, K f   Kanevsky, E f   Bonaca, M P f   Lira Pineda, A f   Hanlon, K f   Knusel, B f   more..

f NONE

Author keywords

[No Author keywords available]

Indexed keywords

EVOLOCUMAB; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9;

EID: 85017341929     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1615664     Document Type: Article
Times cited : (4358)

References (33)
  • 2
    • 84899846576 scopus 로고    scopus 로고
    • A 52-week placebo-controlled trial of evolocumab in hyperlipidemia
    • Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19.
    • (2014) N Engl J Med , vol.370 , pp. 1809-1819
    • Blom, D.J.1    Hala, T.2    Bolognese, M.3
  • 3
    • 84900303213 scopus 로고    scopus 로고
    • Effect of evolocumab or ezetimibe added to moderate-or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: The LAPLACE-2 randomized clinical trial
    • Robinson JG, Nedergaard BS, Rogers WJ, et al. Effect of evolocumab or ezetimibe added to moderate-or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: The LAPLACE-2 randomized clinical trial. JAMA 2014; 311: 1870-82.
    • (2014) JAMA , vol.311 , pp. 1870-1882
    • Robinson, J.G.1    Nedergaard, B.S.2    Rogers, W.J.3
  • 4
    • 84902142901 scopus 로고    scopus 로고
    • Anti-PCSK9 monotherapy for hypercholesterolemia: The MENDEL-2 randomized, controlled phase III clinical trial of evolocumab
    • Koren MJ, Lundqvist P, Bolognese M, et al. Anti-PCSK9 monotherapy for hypercholesterolemia: The MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol 2014; 63: 2531-40.
    • (2014) J Am Coll Cardiol , vol.63 , pp. 2531-2540
    • Koren, M.J.1    Lundqvist, P.2    Bolognese, M.3
  • 5
    • 84902157271 scopus 로고    scopus 로고
    • Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: The GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab
    • Stroes E, Colquhoun D, Sullivan D, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: The GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol 2014; 63: 2541-8.
    • (2014) J Am Coll Cardiol , vol.63 , pp. 2541-2548
    • Stroes, E.1    Colquhoun, D.2    Sullivan, D.3
  • 6
    • 84921483643 scopus 로고    scopus 로고
    • PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): A randomised, double-blind, placebo-controlled trial
    • Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): A randomised, double-blind, placebo-controlled trial. Lancet 2015; 385: 331-40.
    • (2015) Lancet , vol.385 , pp. 331-340
    • Raal, F.J.1    Stein, E.A.2    Dufour, R.3
  • 7
    • 33645103550 scopus 로고    scopus 로고
    • Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
    • Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354: 1264-72.
    • (2006) N Engl J Med , vol.354 , pp. 1264-1272
    • Cohen, J.C.1    Boerwinkle, E.2    Mosley, T.H.3    Hobbs, H.H.4
  • 8
    • 44249122796 scopus 로고    scopus 로고
    • PCSK9 missense variant associated with a reduced risk of earlyonset myocardial infarction
    • Kathiresan S. A PCSK9 missense variant associated with a reduced risk of earlyonset myocardial infarction. N Engl J Med 2008; 358: 2299-300.
    • (2008) N Engl J Med , vol.358 , pp. 2299-2300
    • Kathiresan, S.A.1
  • 9
    • 84926206074 scopus 로고    scopus 로고
    • Efficacy and safety of evolocumab in reducing lipids and cardiovascular events
    • Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-9.
    • (2015) N Engl J Med , vol.372 , pp. 1500-1509
    • Sabatine, M.S.1    Giugliano, R.P.2    Wiviott, S.D.3
  • 10
    • 84926191670 scopus 로고    scopus 로고
    • Efficacy and safety of alirocumab in reducing lipids and cardiovascular events
    • Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99.
    • (2015) N Engl J Med , vol.372 , pp. 1489-1499
    • Robinson, J.G.1    Farnier, M.2    Krempf, M.3
  • 11
    • 84960383006 scopus 로고    scopus 로고
    • Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial
    • Sabatine MS, Giugliano RP, Keech A, et al. Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. Am Heart J 2016; 173: 94-101.
    • (2016) Am Heart J , vol.173 , pp. 94-101
    • Sabatine, M.S.1    Giugliano, R.P.2    Keech, A.3
  • 12
    • 84897970506 scopus 로고    scopus 로고
    • ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
    • Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129: Suppl 2: S1-S45.
    • (2013) Circulation 2014 , vol.129 , pp. S1-S45
    • Stone, N.J.1    Robinson, J.G.2    Lichtenstein, A.H.3
  • 13
    • 11144355354 scopus 로고    scopus 로고
    • Intensive versus moderate lipid lowering with statins after acute coronary syndromes
    • Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-504.
    • (2004) N Engl J Med , vol.350 , pp. 1495-1504
    • Cannon, C.P.1    Braunwald, E.2    McCabe, C.H.3
  • 14
    • 15944410609 scopus 로고    scopus 로고
    • Intensive lipid lowering with atorvastatin in patients with stable coronary disease
    • LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-35.
    • (2005) N Engl J Med , vol.352 , pp. 1425-1435
    • LaRosa, J.C.1    Grundy, S.M.2    Waters, D.D.3
  • 15
    • 84931411520 scopus 로고    scopus 로고
    • Ezetimibe added to statin therapy after acute coronary syndromes
    • Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-97.
    • (2015) N Engl J Med , vol.372 , pp. 2387-2397
    • Cannon, C.P.1    Blazing, M.A.2    Giugliano, R.P.3
  • 16
    • 84977974193 scopus 로고    scopus 로고
    • Baseline LDL-C and clinical outcomes with addition of ezetimibe to statin in 18, 144 patients post ACS
    • abstract
    • Giugliano RP, Cannon C, Blazing M, et al. Baseline LDL-C and clinical outcomes with addition of ezetimibe to statin in 18, 144 patients post ACS. J Am Coll Cardiol 2015; 65: Suppl: A4. abstract.
    • (2015) J Am Coll Cardiol , vol.65
    • Giugliano, R.P.1    Cannon, C.2    Blazing, M.3
  • 17
    • 85007568915 scopus 로고    scopus 로고
    • Effect of evolocumab on progression of coronary disease in statin-Treated patients: The GLAGOV randomized clinical trial
    • Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-Treated patients: The GLAGOV randomized clinical trial. JAMA 2016; 316: 2373-84.
    • (2016) JAMA , vol.316 , pp. 2373-2384
    • Nicholls, S.J.1    Puri, R.2    Anderson, T.3
  • 18
    • 84976361934 scopus 로고    scopus 로고
    • ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents
    • Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2016; 68: 92-125.
    • (2016) J Am Coll Cardiol , vol.2016 , Issue.68 , pp. 92-125
    • Lloyd-Jones, D.M.1    Morris, P.B.2    Ballantyne, C.M.3
  • 19
    • 85016315696 scopus 로고    scopus 로고
    • European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: Practical guidance for use in patients at very high cardiovascular risk
    • October Epub ahead of print
    • Landmesser U, John Chapman M, Farnier M, et al. European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. Eur Heart J 2016 October 27 (Epub ahead of print).
    • (2016) Eur Heart J , vol.27
    • Landmesser, U.1    John Chapman, M.2    Farnier, M.3
  • 20
    • 85019142697 scopus 로고    scopus 로고
    • Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Comparing and contrasting guidance across the Atlantic
    • Epub ahead of print
    • Sabatine MS. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: comparing and contrasting guidance across the Atlantic. Eur Heart J 2017 January 21 (Epub ahead of print).
    • Eur Heart J 2017 January 21
    • Sabatine, M.S.1
  • 21
    • 84989187956 scopus 로고    scopus 로고
    • Interpretation of the evidence for the efficacy and safety of statin therapy
    • Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016; 388: 2532-61.
    • (2016) Lancet , vol.388 , pp. 2532-2561
    • Collins, R.1    Reith, C.2    Emberson, J.3
  • 22
    • 0021350001 scopus 로고
    • The Lipid Research Clinics Coronary Primary Prevention Trial results i Reduction in incidence of coronary heart disease
    • The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-64.
    • (1984) JAMA , Issue.251 , pp. 351-364
  • 23
    • 0023232216 scopus 로고
    • Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-Aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
    • Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-Aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-45.
    • (1987) N Engl J Med , vol.317 , pp. 1237-1245
    • Frick, M.H.1    Elo, O.2    Haapa, K.3
  • 24
    • 0025086998 scopus 로고
    • Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia-report of the Program on the Surgical Control of the Hyperlipidemias (POSCH
    • Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia-report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990; 323: 946-55.
    • (1990) N Engl J Med , vol.323 , pp. 946-955
    • Buchwald, H.1    Varco, R.L.2    Matts, J.P.3
  • 25
    • 78449281377 scopus 로고    scopus 로고
    • Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-Analysis of data from 170, 000 participants in 26 randomised trials
    • The Cholesterol Treatment Trialists' Collaboration
    • The Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-Analysis of data from 170, 000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81.
    • (2010) Lancet , vol.376 , pp. 1670-1681
  • 26
    • 0027987849 scopus 로고
    • Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
    • Scandinavian Simvastatin Survival Study Group
    • Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
    • (1994) Lancet , vol.344 , pp. 1383-1389
  • 27
    • 84879290496 scopus 로고    scopus 로고
    • Unstable angina: Is it time for a requiem?
    • Braunwald E, Morrow DA. Unstable angina: is it time for a requiem? Circulation 2013; 127: 2452-7.
    • (2013) Circulation , vol.127 , pp. 2452-2457
    • Braunwald, E.1    Morrow, D.A.2
  • 28
    • 84995785042 scopus 로고    scopus 로고
    • Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: A systematic review and meta-Analysis
    • Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: A systematic review and meta-Analysis. JAMA 2016; 316: 1289-97.
    • (2016) JAMA , vol.316 , pp. 1289-1297
    • Silverman, M.G.1    Ference, B.A.2    Im, K.3
  • 29
    • 84999053643 scopus 로고    scopus 로고
    • Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes
    • Ference BA, Robinson JG, Brook RD, et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N Engl J Med 2016; 375: 2144-53.
    • (2016) N Engl J Med , vol.375 , pp. 2144-2153
    • Ference, B.A.1    Robinson, J.G.2    Brook, R.D.3
  • 30
    • 77549087054 scopus 로고    scopus 로고
    • Statins and risk of incident diabetes: A collaborative meta-Analysis of randomised statin trials
    • Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: A collaborative meta-Analysis of randomised statin trials. Lancet 2010; 375: 735-42.
    • (2010) Lancet , vol.375 , pp. 735-742
    • Sattar, N.1    Preiss, D.2    Murray, H.M.3
  • 31
    • 79959428660 scopus 로고    scopus 로고
    • Risk of incident diabetes with intensivedose compared with moderate-dose statin therapy: A meta-Analysis
    • Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensivedose compared with moderate-dose statin therapy: A meta-Analysis. JAMA 2011; 305: 2556-64.
    • (2011) JAMA , vol.305 , pp. 2556-2564
    • Preiss, D.1    Seshasai, S.R.2    Welsh, P.3
  • 32
    • 85009999641 scopus 로고    scopus 로고
    • Press release from Pfizer, New York, November 1
    • Pfizer discontinues global development of bococizumab, its investigational PCSK9 inhibitor. Press release from Pfizer, New York, November 1, 2016 (http://www .pfizer .com/news/press-release/press-release-detail/Pfizer-discontinues-global-development-of-bococizumab-its-investigational-pcsk9-inhibitor).
    • (2016) Pfizer Discontinues Global Development of Bococizumab, Its Investigational PCSK9 Inhibitor
  • 33
    • 85020684247 scopus 로고    scopus 로고
    • Long-Term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: Results up to 4 years from the open-label OSLER-1 extension study
    • Epub ahead of print
    • Koren MJ, Sabatine MS, Giugliano RP, et al. Long-Term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: results up to 4 years from the open-label OSLER-1 extension study. JAMA Cardiol 2017 March 14 (Epub ahead of print).
    • JAMA Cardiol 2017 March 14
    • Koren, M.J.1    Sabatine, M.S.2    Giugliano, R.P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.